Cancer Therapeutics has announced the validation and performance of CTx-294886 in combination with Avastin in a preclinical model of basal breast cancer. The CTx-0294886, a potent small molecule inhibitor of Focal Adhesion Kinase (FAK) ...
Tags: cancer therapeutics, CTx-294886, basal breast cancer, FAK inhibitor